It’s official: Sanofi is finally ready to unload its European generics business. More than two months after disclosing that they were in exclusive talks, the French drugmaker and buyer Advent International have ironed out the details on a €1.9 billion
read moreGone but not forgotten. A year after the NotPetya cyberattack took down the manufacturing and other operations of Merck & Co., the industry continues to feel the impact. More: Merck has hardened its defenses against cyberattacks like the one last
read moreNHS England has announced two more regions chosen to become Local Health and Care Record Exemplars (LHCRE), tasked with establishing an integrated health and care record across a large population. More: NHS England expands health and care record scheme Source:
read moreRoche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, over-turning a prior decision to reject NHS funding for the drug. More: NICE backs Roche’s Alecensa Source: News
read moreAcelRx’ Dzuveo has won approval in the European Unionl for the management of acute moderate to severe pain in medically monitored settings. More: EU approval for AcelRx' Dzuveo Source: News
read moreThe US Food and Drug Administration will undertake a priority review of Genentech’s experimental flu drug baloxavir marboxil in people aged 12 years and older. More: Priority review for Genentech’s flu drug Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals